Nuclera Nucleics Stock

Enzymatic DNA synthesis

Sign up today and learn more about Nuclera Nucleics Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About Nuclera Nucleics Stock

Nuclera is a next-generation DNA synthesis company creating tailored solutions for the synthetic biology, industrial enzyme engineering, and pharmaceutical industries. Our proprietary enzyme-mediated DNA synthesis platform will enable the rapid and cost-effective production of highly accurate, ultra-long DNA strands. We aim to be the key provider of long-length variant DNA and genome libraries for protein, biological pathway, and ultimately genome-scale engineering.

Funding History

March 2014$500K
April 2014$100K
June 2014$25K
April 2015$203K

Press

patents - Apr, 13 2024

Protein purification

patents - Apr, 13 2024

Controlled reservoir filling

patents - Apr, 13 2024

Protein binding assays

patents - Apr, 13 2024

Improved fluorescent proteins

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

Logo